Sun Pharma and Cipla seen as having more upside
Systematix analyst Vishal Manchanda said Sun Pharmaceutical Industries and Cipla offer relatively better upside among large-cap pharma stocks. He added that increasing licensing deals with Chinese drugmakers could help lower oncology drug prices in India.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.